Navigation Links
Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners
Date:11/27/2007

BRISBANE, Australia, Nov. 27 /PRNewswire/ -- Xenome Ltd, a specialist biopharmaceutical company developing novel peptide drugs, announced today that it has successfully raised US$10M of equity finance. The syndicated funding round includes continuing support from Xenome's major investor, Queensland BioCapital Funds (QBF), for $2.7M, significant equity funding of $5m from Amylin Pharmaceuticals Inc, a top tier USA biotechnology company headquartered in San Diego, California, and $2.3M from Innovis Investment Partners (Innovis).

The combined investment will enable Xenome to continue the execution of its operational plan which includes:
- Implementation of a Joint Xenome-Amylin Research Collaboration

involving drug discovery of new compounds from Xenome's unique

peptide library using Amylin's assay technologies in the fields of

metabolic and musculoskeletal diseases;

- Expansion of the Phase 2 clinical development of Xenome's most

advanced and promising drug candidate, Xen2174, for the treatment of

acute and chronic intractable pain and;

- Furthering the development of Xenome's current drug candidate

pipeline.

"The opportunity to make two major announcements on the same day does not come around very often, so it is satisfying to be able to announce this new syndicated investment by QBF, Amylin and Innovis together with the execution of the separate Joint Xenome-Amylin Research Collaboration. The Company recognizes QBF's sustained support and belief in Xenome at a time when biotech funding comes at a premium. At the same time we welcome new substantial shareholders Amylin and Innovis Ltd. to the Company's share register." said Xenome CEO, Lewis Lee.

"The equity investment integrated with the extensive Xenome-Amylin Joint Research Collaboration provides a tremendous validation of the Company's peptide drug discovery platform and will facilitate Xenome's ability to rapidly ge
'/>"/>

SOURCE Xenome Ltd
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
5. IsoTis Receives FDA Clearance for Accell Family of Products
6. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
7. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
8. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
9. XTL Receives Staff Letter From NASDAQ
10. XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market
11. Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 3, 2015  ArroGen Group, an integrated advanced ... Molecular Identification™ (FMID) technology Aug. 2-8 at the ... Sacramento, Calif. FMID, ... law enforcement agents, district attorneys and government agencies ... By analyzing chemical residues on fingerprints ...
(Date:8/3/2015)... At the 11th hour, London,s ... of Jude Liversage,s campaign so the seven-year-old ...      (Photo: http://photos.prnewswire.com/prnh/20150803/254228 ) ... The Selective Dorsal Rhizotomy (SDR) procedure reduced the spasticity ... wish to kick a ball around like his schoolmates. ...
(Date:8/3/2015)...  MiMedx Group, Inc. (NASDAQ: MDXG ), the ... patent-protected processes to develop and market advanced products and ... Medicine, Ophthalmic and Dental sectors of healthcare, announced today ... Annual Canaccord|Genuity Growth Conference in Boston, Massachusetts ... William C. Taylor , President and COO, and ...
(Date:8/3/2015)... ... August 03, 2015 , ... The synthetic ... to get such derivatives as ethylbenzene, a precursor to styrene, used to make ... automotive industry for the production of tyres and other components. Thus, growth in ...
Breaking Biology Technology:ArroGen Previews New Fingerprint Molecular Identification Technology 2Cerebral Palsy Operation by The Portland Hospital Allows a Boy to Stand Properly for the First Time 2Cerebral Palsy Operation by The Portland Hospital Allows a Boy to Stand Properly for the First Time 3MiMedx To Present At 35th Annual Canaccord|Genuity Growth Conference 2World Benzene Market to Surpass 46 MMT by 2020, According to TechSci Research Report Published at MarketPublishers.com 2World Benzene Market to Surpass 46 MMT by 2020, According to TechSci Research Report Published at MarketPublishers.com 3
... (Nasdaq: BIOD ) today announced that Dr. ... present a corporate update at the 29th Annual JPMorgan ... a.m. Pacific Time (12:30 p.m. Eastern Time). The update ... formulations of its lead product, Linjeta™, including milestones and ...
... SAN DIEGO, Jan. 6, 2011 Ardea Biosciences, Inc. ... top-line results from its Phase 2b study of RDEA594 ... the treatment of gout, allopurinol.  Allopurinol currently accounts for ... gout prescription medications; however, in controlled trials, only 30-40% ...
... Mass., Jan. 6, 2011 GENFIT (Alternext: ALGFT; ISIN: ... discovery and development, focusing on the early diagnosis and ... its presence at two U.S. events: the 28th J.P. ... and the Biotech Showcase (from January 10th to 12th, ...
Cached Biology Technology:Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 2Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 3Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 4Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 5Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 6Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 7GENFIT: Strong U.S. Exposure for Its Biomarker Activity 2GENFIT: Strong U.S. Exposure for Its Biomarker Activity 3
(Date:7/31/2015)... -- Den 10. internationale konference om Genomik (ICG-10, ... 25. oktober i Shenzhen , Kina. ... år. Siden starten i 2006 er ICB blevet en ... er en af de mest dynamiske, entusiastiske og sjove ... gennembrud og fremskridt inden for ,omik,-forskning, som yderligere vil ...
(Date:7/31/2015)... China , 31 de julio de 2015 /PRNewswire/ ... Genómica (ICG-10,  www.icg-10.org ) del 22 al 25 de ... . La conferencia celebra su décimo aniversario ... ha convertido en una de las reuniones anuales más ... y es una de las conferencias científicas más dinámicas, ...
(Date:7/31/2015)... de 2015 A 10 a. Conferência ... pela BGI de 22-25 de outubro de 2015, em ... conferência está celebrando seu 10 o. aniversário este ano. ... uma das reuniões mais influentes do mundo no ramo ... entusiastas e prazerosos. A ICG-10 se ...
Breaking Biology News(10 mins):Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... Nearly 50% of couples who were interviewed at least 3 ... their surplus, stored embryos for stem cell research, according to ... April 26, 2007, advanced online publication of Cell Stem Cell, ... International Society for Stem Cell Research. , The key ...
... MIT Media Lab have invented a way to reversibly ... the prospect of controlling the haywire neuron activity that ... , Such diseases often must be treated by removing ... lead to the development of optical brain prosthetics to ...
... Dick at Ontario Cancer Institute (OCI) have developed a method ... stem cells. The converted cells, when transplanted into special mice ... entire disease process from the very moment it begins. The ... Dick, Senior Scientist at OCI, the research arm of Princess ...
Cached Biology News:Many couples choose to donate surplus embryos for stem cell research 2MIT: Pulsing light silences overactive neurons 2Cancer scientists create 'human' leukemia process to map how disease begins, progresses 2
The DNA DipStick Kit is ideal for estimating nucleic acid concentrations and approximate yields. Works with ss- and ds-DNA, RNA, and oligonucleotides at concentrations as low as 0.1 ng/l....
IHC detection kit for PCNA in cells and tissues...
Request Info...
... Synthetic peptide derived from the C-terminal ... Specificity: Reacts with the human ... Human Mouse (positive controls: WNT1-transfected HEK293 ... and mouse Mouse-1 cell lysates). ...
Biology Products: